Updated Analysis of an Open-Label, Phase 2 Study of Blinatumomab As Second Salvage Therapy in Adults with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

被引：2
|
作者：
Coyle, Luke
Morley, Nicholas J.
Rambaldi, Alessandro
Mason, Kylie D.
Verhoef, Gregor
Furness, Caroline
Desai, Rajendra
Mergen, Noemi
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-141117
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
    Coyle, Luke
    Morley, Nicholas J.
    Rambaldi, Alessandro
    Mason, Kylie D.
    Verhoef, Gregor
    Furness, Caroline L.
    Zhang, Alicia
    Jung, A. Scott
    Cohan, David
    Franklin, Janet L.
    LEUKEMIA & LYMPHOMA, 2020, 61 (09) : 2103 - 2112
  • [2] Open-Label, Phase 2 Study of Blinatumomab As Second Salvage Therapy in Adults with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
    Coyle, Luke
    Morley, Nicholas J.
    Rambaldi, Alessandro
    Mason, Kylie D.
    Verhoef, Gregor
    Furness, Caroline
    Zhang, Alicia
    Jung, A. Scott
    Franklin, Janet L.
    BLOOD, 2018, 132
  • [3] Durability of complete response after blinatumomab therapy for refractory/relapsed aggressive B-cell non-Hodgkin lymphoma.
    Viardot, Andreas
    Hess, Georg
    Bargou, Ralf C.
    Morley, Nicholas
    Gritti, Giuseppe
    Iskander, Karim
    Cohan, David
    Zhang, Alicia
    Franklin, Janet
    Coyle, Luke
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
    Hutchings, Martin
    Mous, Rogier
    Clausen, Michael Roost
    Johnson, Peter
    Linton, Kim M.
    Chamuleau, Martine E. D.
    Lewis, David John
    Balari, Anna Sureda
    Cunningham, David
    Oliveri, Roberto S.
    Elliott, Brian
    DeMarco, Dena
    Azaryan, Ada
    Chiu, Christopher
    Li, Tommy
    Chen, Kuo-mei
    Ahmadi, Tahamtan
    Lugtenburg, Pieternella J.
    LANCET, 2021, 398 (10306): : 1157 - 1169
  • [5] Treatment of relapsed/refractory paediatric aggressive B-cell non-Hodgkin lymphoma
    Moleti, Maria L.
    Testi, Anna M.
    Foa, Robin
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 (05) : 826 - 843
  • [6] Efficacy of Gemcitabine as Salvage Therapy for Relapsed and Refractory Aggressive Non-Hodgkin Lymphoma
    Zlotnick, Maya
    Avigdor, Abraham
    Ribakovsky, Elena
    Nagler, Arnon
    Kedmi, Meirav
    ACTA HAEMATOLOGICA, 2019, 141 (02) : 84 - 90
  • [7] Therapy for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma in Children, Adolescents, and Young Adults
    Gardenswartz, Aliza
    Cairo, Mitchell S.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2024, 22 (05):
  • [8] A phase II, single-arm, open-label study of pralatrexate in patients with aggressive relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL): Study PDX-015
    Chang, J. E.
    Rosen, P. J.
    Diefenbach, C. S. Magid
    Kacprowicz, H.
    O'Connor, O.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma
    Barr, Paul M.
    Miller, Thomas P.
    Friedberg, Jonathan W.
    Peterson, Derick R.
    Baran, Andrea M.
    Herr, Megan
    Spier, Catherine M.
    Cui, Haiyan
    Roe, Denise J.
    Persky, Daniel O.
    Casulo, Carla
    Littleton, Jamie
    Schwartz, Mark
    Puvvada, Soham
    Landowski, Terry H.
    Rimsza, Lisa M.
    Dorr, Robert T.
    Fisher, Richard I.
    Bernstein, Steven H.
    Briehl, Margaret M.
    BLOOD, 2014, 124 (08) : 1259 - 1265
  • [10] Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
    Makita, Shinichi
    Yamamoto, Go
    Maruyama, Dai
    Asano-Mori, Yuki
    Kaji, Daisuke
    Ananthakrishnan, Revathi
    Ogasawara, Ken
    Stepan, Lara
    Schusterbauer, Claudia
    Rettby, Nils
    Hasskarl, Jens
    Izutsu, Koji
    CANCER MEDICINE, 2022, 11 (24): : 4889 - 4899
12345